Impact of CYP1A1, GSTM1, and GSTT1 polymorphisms in overall and specific prostate cancer survival
Author
dc.contributor.author
Acevedo, Cristián A.
Author
dc.contributor.author
Quiñones, Luis A.
Author
dc.contributor.author
Catalán, Johanna
Author
dc.contributor.author
Cáceres, Dante D.
Author
dc.contributor.author
Fullá, Juan A.
Author
dc.contributor.author
Roco, Angela M.
Admission date
dc.date.accessioned
2019-03-15T16:06:08Z
Available date
dc.date.available
2019-03-15T16:06:08Z
Publication date
dc.date.issued
2014
Cita de ítem
dc.identifier.citation
Urologic Oncology: Seminars and Original Investigations, Volumen 32, Issue 3, 2018, Pages 280-290
Identifier
dc.identifier.issn
18732496
Identifier
dc.identifier.issn
10781439
Identifier
dc.identifier.other
10.1016/j.urolonc.2013.05.010
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/166126
Abstract
dc.description.abstract
Objective: Prognostic biomarkers that distinguish between patients with good or poor outcome can be used to guide decisions of whom to treat and how aggressively. In this sense, several groups have proposed genetic polymorphisms as potential susceptibility and prognostic biomarkers; however, their validity has not been proven. Thus, the main goal of the present work was to investigate the potential role of single and combined CYP1A1, GSTM1, and GSTT1 genotypes as modifiers of cancer survival in Chilean patients with prostate cancer. Methods and materials: A total of 260 histologically confirmed patients were recruited from a voluntary screening, and genomic DNA was obtained from their blood samples for genotyping analyses to detect the CYP1A1*2A polymorphism and GSTM1 and GSTT1 deletions. The progression of illness and mortality were estimated with a median follow-up of 8.82 years. Adjusted estimated genotype risks were evaluated by hazard ratio and 95% CI using the Cox proportional mo